FDA Clears SPR Therapeutics’ Non-Opioid Peripheral Nerve Stimulation Systems For Pain Management

The U.S. Food and Drug Administration (FDA) recently cleared SPR Therapeutics’ (SPR) SPRINT endura and extensa Peripheral Nerve Stimulation (PNS) systems for the treatment of chronic and acute pain. To date, the SPRINT PNS platform is the only FDA cleared percutaneous (effected through the skin) PNS System.

SPRINT PNS is designed specifically for the periphery to deliver sustained, significant pain relief without drugs, implants, anesthesia, or incisions. According to SPR leadership, the platform also seeks to deliver PNS therapy in the least invasive and user-friendly manner, providing individuals with a non-opioid therapy alternative to pain treatment. The . . .